Accelerated Deep TMS Protocol
Major Depressive Disorder
FDA ClearedCommercializing
Key Facts
About BrainsWay
BrainsWay is a commercial-stage medical device company with a mission to boldly advance neuroscience to improve health and transform lives. Its core achievement is the development and FDA clearance of its Deep TMS platform for multiple psychiatric indications, establishing it as a leader in noninvasive neuromodulation. The company's strategy focuses on expanding its cleared indications, optimizing treatment protocols, and growing its global installed base through direct sales and strategic partnerships. BrainsWay leverages a robust body of clinical evidence to drive adoption among providers and payers.
View full company profileTherapeutic Areas
Other Major Depressive Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| ZURZUVAE (zuranolone) | Sage Therapeutics | Phase 3 |
| MDD Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| NMDAR Antagonist (GM-2505/Bretisilocin) | Gilgamesh Pharmaceuticals | Phase 2 |
| Neuroplastogen (GM-1020) | Gilgamesh Pharmaceuticals | Phase 2a |
| NA-901 | Biomed | Phase 2B/3 |
| SP-624 (Forvisirvat) | Arrivo BioVentures | Phase 2 |
| NBS System for MDD | Nexstim | Approved |
| NeuroStar for MDD | Neuronetics | Approved |
| Major Depressive Disorder Studies | Noesis Pharma Clinical Trials | Phase 2-4 |
| Depression Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| Neurotyping Platform for MDD | Universal Brain | Development |
| Ansofaxine (TP1) | Sumitomo Pharma | Filed (US) |